Skip to content
Medical Health Aged Care

The natural defences of ticks could help improve anti-inflammatory drugs

Monash University 2 mins read

Monash University-led research is using ticks to help unlock better ways to fight inflammation, which causes considerable suffering in people globally.

Monash Biomedicine Discovery Institute-led team has ‘hijacked’ an anti-inflammatory mechanism used by ticks to block the activity of proteins important in human inflammatory diseases. 

Chronic inflammatory diseases like atherosclerosis, pulmonary fibrosis, rheumatoid arthritis and cancers cause much suffering worldwide. 

The associated inflammation is caused by the release of proteins called chemokines in the affected tissues, so researchers are seeking ways to block the activity of chemokines. 

Conducted by PhD student
Shankar Devkota and published in Nature Communications, this study discovered a new family of tick salivary proteins called A3 evasins. 

These evasins can block numerous chemokines, suggesting they could be repurposed to target chemokines involved in human inflammatory diseases. 

By analysing the 3D structures of these evasins and their interactions with chemokines, the team designed and engineered evasin variants that inhibit chemokines involved in atherosclerosis and rheumatoid arthritis. 

Co-senior Author
Dr Ram Bhusal, of the Monash Biomedicine Discovery Institute, said this proof-of-principle study laid a foundation for the future development of engineered evasins that could be used to develop improved inflammation treatments.

“It turns out that ticks have naturally evolved the ability to block chemokine-driven inflammation, which enables them to live on their hosts for extended periods without the host being aware of them,” he said. 

Dr Bhusal said the tick evasins were special because no current anti-inflammatory drugs were designed to target chemokines directly. 

“The tick-derived evasins represent a novel class of anti-inflammatory agents with a distinct mode of action to inhibit chemokines,” he said. “As such, they offer a fresh perspective and an alternative strategy for reducing inflammation in the body.”

Co-senior author
Professor Martin Stone said more research and human trials were needed, but the development was promising.

“This finding is significant because it opens up possibilities for developing a new generation of anti-inflammatory drugs,” he said. “These new drugs could improve the treatment options for patients with chronic inflammatory diseases, potentially saving lives and reducing suffering.”

Read the full paper in
Nature Communications: Engineering broad-spectrum inhibitors of inflammatory chemokines from subclass A3 tick evasins. 

This research was largely funded by the National Health and Medical Research Council (NHMRC) and Monash University. The work was conducted in collaboration with the ARC Centre of Excellence for Innovations in Peptide and Protein Science (


For media enquiries please contact:

Monash University

Cheryl Critchley - Communications Manager (medical)

T: +61 (0) 418 312 596

For more Monash media stories, visit our news and events site  

For general media enquiries please contact:
Monash Media
T: +61 (0) 3 9903 4840

About the Monash Biomedicine Discovery Institute

Committed to making the discoveries that will relieve the future burden of disease, the Monash Biomedicine Discovery Institute (BDI) at Monash University brings together more than 120 internationally-renowned research teams. Spanning seven discovery programs across Cancer, Cardiovascular Disease, Development and Stem Cells, Infection, Immunity, Metabolism, Diabetes and Obesity, and Neuroscience, Monash BDI is one of the largest biomedical research institutes in Australia. Our researchers are supported by world-class technology and infrastructure, and partner with industry, clinicians and researchers internationally to enhance lives through discovery.


More from this category

  • Environment, Medical Health Aged Care
  • 01/12/2023
  • 10:43
West Australian doctors peak bodies

WA doctors and health professionals call for the government to take urgent action on climate change and end fossil fuel expansion to protect health

On the 1st December, just prior to the COP28 Health Day on the 3rd December, representatives of the medical colleges for general practitioners (GPs), emergency doctors, rural and remote doctors, and surgeons, as well as other doctors and health professionals, gather at 8 am on the steps of Parliament House to call on the WA Government take urgent action on climate change and protect the health of Western Australians. Reiterating calls from medical colleges earlier this year in support of ending fossil fuel expansion and climate action, those gathered today ask the WA government to: End expansion of any new…

  • Medical Health Aged Care
  • 01/12/2023
  • 10:12
Australian Dental Industry Association

ADIA congratulates Senators of the Inquiry into the Provision of and Access to Dental Services in Australia

1 December The Australian Dental Industry Association congratulates the Senators of the Senate Select Committee Inquiry into the Provision of and Access to Dental…

  • Contains:
  • Medical Health Aged Care, Research Development
  • 01/12/2023
  • 09:17

Aegros Releases Top-Line Interim Clinical Trial Results of its COVID-19 Hyperimmune

Aegros Releases Top-Line Interim Clinical Trial Results of its COVID-19 Hyperimmune Aegros, an Australian clinical-stage biopharmaceutical company leader in the development and manufacture of plasma derived medicinal products (PDMPs), today announced positive top-line interim results from its CHAT clinical trial. Top-line interim results indicate that Aegros’ COVID-19 hyperimmune provides higher levels of antibodies compared to high-titer convalescent plasma. These results are in line with Aegros’ pre-clinical expectations. CHAT compared Aegros’ COVID-19 hyperimmune to COVID-19 convalescent plasma. The hyperimmune was manufactured using Aegros’ patented Haemafrac® process. A hyperimmune is an intravenous immunoglobulin rich in antibodies that can provide passive immunity for…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time your distribute with Medianet. Pay per release or save with a subscription.